The genetics of Parkinson’s disease: progress and therapeutic implications
Identifieur interne : 001382 ( Ncbi/Curation ); précédent : 001381; suivant : 001383The genetics of Parkinson’s disease: progress and therapeutic implications
Auteurs : Andrew B. Singleton [États-Unis] ; Matthew J. Farrer [Canada] ; Vincenzo Bonifati [Pays-Bas]Source :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2013.
Abstract
The past 15 years has witnessed tremendous progress in our understanding of the genetic basis for Parkinson’s disease (PD). Notably, while most mutations, such as those in
There has been considerable progress in finding risk loci. To date approximately 16 such loci exist, notably some of these overlap with the genes known to contain disease-causing mutations. The identification of risk alleles has relied mostly on the application of revolutionary technologies; likewise second generation sequencing methods have facilitated the identification of new mutations in
The utility of genetics in therapeutics relies primarily on leveraging findings to understand the pathogenesis of PD. Much of the investigation into the biology underlying PD has used these findings to define a pathway, or pathways, to pathogenesis, by trying to fit disparate genetic defects onto the same network. This work has had some success, particularly in the context of monogenic disease and is beginning to provide clues about potential therapeutic targets. Approaches toward therapies are also being provided more directly by genetics; notably via the reduction and clearance of α-synuclein and inhibition of Lrrk2 kinase activity.
We believe this has been an exciting and productive time for PD genetics, and furthermore, that genetics will continue to drive the etiologic understanding and etiology based therapeutic approaches in this disease.
Url:
DOI: 10.1002/mds.25249
PubMed: 23389780
PubMed Central: 3578399
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000833
- to stream Pmc, to step Curation: Pour aller vers cette notice dans l'étape Curation :000833
- to stream Pmc, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000566
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :001382
Links to Exploration step
PMC:3578399Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The genetics of Parkinson’s disease: progress and therapeutic implications</title>
<author><name sortKey="Singleton, Andrew B" sort="Singleton, Andrew B" uniqKey="Singleton A" first="Andrew B." last="Singleton">Andrew B. Singleton</name>
<affiliation wicri:level="1"><nlm:aff id="A1">Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland 20892, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland 20892</wicri:regionArea>
<wicri:noRegion>Maryland 20892</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Farrer, Matthew J" sort="Farrer, Matthew J" uniqKey="Farrer M" first="Matthew J." last="Farrer">Matthew J. Farrer</name>
<affiliation wicri:level="1"><nlm:aff id="A2">Department of Medical Genetics, University of British Columbia, Vancouver, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medical Genetics, University of British Columbia, Vancouver</wicri:regionArea>
<wicri:noRegion>Vancouver</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bonifati, Vincenzo" sort="Bonifati, Vincenzo" uniqKey="Bonifati V" first="Vincenzo" last="Bonifati">Vincenzo Bonifati</name>
<affiliation wicri:level="1"><nlm:aff id="A3">Department of Clinical Genetics, Erasmus MC, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands</nlm:aff>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Clinical Genetics, Erasmus MC, P.O. Box 2040, 3000 CA Rotterdam</wicri:regionArea>
<wicri:noRegion>3000 CA Rotterdam</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">23389780</idno>
<idno type="pmc">3578399</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3578399</idno>
<idno type="RBID">PMC:3578399</idno>
<idno type="doi">10.1002/mds.25249</idno>
<date when="2013">2013</date>
<idno type="wicri:Area/Pmc/Corpus">000833</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000833</idno>
<idno type="wicri:Area/Pmc/Curation">000833</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000833</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000566</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000566</idno>
<idno type="wicri:Area/Ncbi/Merge">001382</idno>
<idno type="wicri:Area/Ncbi/Curation">001382</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">The genetics of Parkinson’s disease: progress and therapeutic implications</title>
<author><name sortKey="Singleton, Andrew B" sort="Singleton, Andrew B" uniqKey="Singleton A" first="Andrew B." last="Singleton">Andrew B. Singleton</name>
<affiliation wicri:level="1"><nlm:aff id="A1">Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland 20892, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland 20892</wicri:regionArea>
<wicri:noRegion>Maryland 20892</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Farrer, Matthew J" sort="Farrer, Matthew J" uniqKey="Farrer M" first="Matthew J." last="Farrer">Matthew J. Farrer</name>
<affiliation wicri:level="1"><nlm:aff id="A2">Department of Medical Genetics, University of British Columbia, Vancouver, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medical Genetics, University of British Columbia, Vancouver</wicri:regionArea>
<wicri:noRegion>Vancouver</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bonifati, Vincenzo" sort="Bonifati, Vincenzo" uniqKey="Bonifati V" first="Vincenzo" last="Bonifati">Vincenzo Bonifati</name>
<affiliation wicri:level="1"><nlm:aff id="A3">Department of Clinical Genetics, Erasmus MC, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands</nlm:aff>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Clinical Genetics, Erasmus MC, P.O. Box 2040, 3000 CA Rotterdam</wicri:regionArea>
<wicri:noRegion>3000 CA Rotterdam</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><date when="2013">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p id="P1">The past 15 years has witnessed tremendous progress in our understanding of the genetic basis for Parkinson’s disease (PD). Notably, while most mutations, such as those in <italic>SNCA, PINK1</italic>
, <italic>PARK2</italic>
, <italic>PARK7</italic>
, <italic>PLA2G6</italic>
, <italic>FBXO7</italic>
, and <italic>ATP13A2</italic>
, are a rare cause of disease, one particular mutation in <italic>LRRK2</italic>
, has been found to be common in certain populations.</p>
<p id="P2">There has been considerable progress in finding risk loci. To date approximately 16 such loci exist, notably some of these overlap with the genes known to contain disease-causing mutations. The identification of risk alleles has relied mostly on the application of revolutionary technologies; likewise second generation sequencing methods have facilitated the identification of new mutations in <italic>PD</italic>
. These methods will continue to provide novel insights into PD.</p>
<p id="P3">The utility of genetics in therapeutics relies primarily on leveraging findings to understand the pathogenesis of PD. Much of the investigation into the biology underlying PD has used these findings to define a pathway, or pathways, to pathogenesis, by trying to fit disparate genetic defects onto the same network. This work has had some success, particularly in the context of monogenic disease and is beginning to provide clues about potential therapeutic targets. Approaches toward therapies are also being provided more directly by genetics; notably via the reduction and clearance of α-synuclein and inhibition of Lrrk2 kinase activity.</p>
<p id="P4">We believe this has been an exciting and productive time for PD genetics, and furthermore, that genetics will continue to drive the etiologic understanding and etiology based therapeutic approaches in this disease.</p>
</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001382 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 001382 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Canada |area= ParkinsonCanadaV1 |flux= Ncbi |étape= Curation |type= RBID |clé= PMC:3578399 |texte= The genetics of Parkinson’s disease: progress and therapeutic implications }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:23389780" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \ | NlmPubMed2Wicri -a ParkinsonCanadaV1
This area was generated with Dilib version V0.6.29. |